1174020-51-9

Basic information

• Product Name: tert-butyl (3S,4S)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate
• Synonyms: tert-butyl (3S,4S)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate
• CAS NO: 1174020-51-9
• Molecular Formula: C9H16FNO3
• Molecular Weight: 205.2266432
• Mol File: 1174020-51-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: tert-butyl (3S,4S)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl (3S,4S)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate(1174020-51-9)
• EPA Substance Registry System: tert-butyl (3S,4S)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate(1174020-51-9)

Safety Data

• Hazardous Substances Data: 1174020-51-9(Hazardous Substances Data)

Usage

General Description

Tert-butyl (3S,4S)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate is a chemical compound with the molecular formula C9H16FNO3. It is a derivative of pyrrolidine, a heterocyclic organic compound. tert-butyl (3S,4S)-3-fluoro-4-hydroxypyrrolidine-1-carboxylate is commonly used in pharmaceutical research and drug development due to its potential biological activity. It is of interest for its potential to act as a building block for the synthesis of various pharmaceutical agents. The tert-butyl group in the compound provides stability and protection to the functional groups of the molecule, making it a useful intermediate for the synthesis of other complex organic compounds. Additionally, the presence of the fluoro and hydroxy groups in the pyrrolidine ring adds to the compound's potential for pharmacological activity.

Upstream product

• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 151259-38-0 tert-butyl diallylcarbamate 

Downstream Products

• 1309682-76-5 3-hydroxy-4-fluoropyrrolidine 
• 1334320-82-9 (3S,4R)-4-fluoropyrrolidin-3-ol 
• 1334320-82-9 (3S,4S)-4-fluoropyrrolidin-3-ol 
• 845894-03-3 tert-butyl 3-fluoro-4-oxopyrrolidine-1-carboxylate 

Relevant articles and documents

(HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY

Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition comprising the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase for preparing a plurality of drugs comprising an anti-tumour drug.

5-PHENYLAZAINDOLE DERIVATIVE HAVING AMPK ACTIVATING EFFECT

Provided is a compound which is useful as an AMPK activator. A compound represented by formula: wherein X is substituted or unsubstituted monocyclic heterocyclyl or the like; ring A is substituted aryl, substituted heteroaryl, substituted cycloalkyl, substituted cycloalkenyl, or substituted heterocyclyl, wherein the ring A may further have a substituent(s) other than Y; Y is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like; R4, R5, R6 and R7 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkyloxy, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted acyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted sulfamoyl, or substituted or unsubstituted amino; R8 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like; and R9 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or the like, or its pharmaceutically acceptable salt.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.